{"id":"emtricitabine-darunavir-cobicistat-maraviroc","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Lipid abnormalities"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase. Darunavir is a protease inhibitor that prevents HIV protease from cleaving viral polyproteins. Cobicistat is a pharmacokinetic booster that inhibits CYP3A4, increasing darunavir plasma concentrations. Maraviroc is a CCR5 antagonist that blocks the CCR5 co-receptor on CD4+ T cells, preventing viral entry.","oneSentence":"This is a three-drug combination that inhibits HIV replication through multiple mechanisms: emtricitabine and darunavir block reverse transcriptase and protease respectively, cobicistat enhances darunavir levels, and maraviroc blocks the CCR5 co-receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:45:23.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced patients with CCR5-tropic virus"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03163277","phase":"PHASE4","title":"Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)","status":"TERMINATED","sponsor":"Giovanni Di Perri","startDate":"2017-05-15","conditions":"Hiv, Neurocognitive Dysfunction","enrollment":38},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"emtricitabine, darunavir/cobicistat, maraviroc","genericName":"emtricitabine, darunavir/cobicistat, maraviroc","companyName":"Giovanni Di Perri","companyId":"giovanni-di-perri","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a three-drug combination that inhibits HIV replication through multiple mechanisms: emtricitabine and darunavir block reverse transcriptase and protease respectively, cobicistat enhances darunavir levels, and maraviroc blocks the CCR5 co-receptor. Used for HIV-1 infection in treatment-experienced patients with CCR5-tropic virus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}